Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts 2010 - 2017
In the overall Asthma and COPD market, Advair remained the market leader with USD 7,802 million in 2011 and is expected to reach USD xxxx million in 2014. Singulair is the second largest drug in terms of revenue at UD 5479 million in 2011. The patent that provides U.S. market exclusivity for Singulair will expire in August 2012. It is expected that within 2-3 years following patent expiration, it will lose substantially all U.S. sales of Singulair, with most of those declines coming in the first full year following patent expiration. Also, the patent that provides market exclusivity for Singulair will expire in a number of major European markets in February 2013 and sales of Singulair in those markets will decline significantly thereafter. The patent that provides market exclusivity for Singulair in Japan will expire in 2016.
Asia Pacific region commanded for the largest share of global Asthma patients in 2010. The North America region will have the fastest growth rate for asthma patients at a CAGR of 3.9% in the world during 2010 - 2017. Globally, patients numbers are increasing continuously primarily due to cigarette smoking, continual exposure to hazardous particles or gases, increase in urbanization, change in lifestyle, and genetic factors. The growing number of asthmatics people from china and other economies will drive the revenue growth for the Asthma and COPD drugs market.
At present, long-acting beta2 agonist (LABA) / inhaled corticosteroid (ICS) combinations are the preferred combinations in the U.S. for treatment of asthma and/or COPD that include Advair (GlaxoSmithKline), Symbicort (AstraZeneca), and Dulera (Merck). LABA/ICS combinations are the most prescribed drugs because they offer efficacy and the convenience of delivering two drugs in one inhaler. The U.S. sales for asthma and COPD drugs are expected to total more than USDxxxx billion in 2012.
In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment. Merck's branded product Singulair contains Montelukast sodium, which is a leading oral anti-asthma and anti-allergy drug. Singulair is one of the trusted drugs for the treatment of chronic asthma, and for the relief of symptoms of seasonal allergic rhinitis. Currently, Montelukast is the largest selling anti-asthmatic drug worldwide.
For COPD patients, physicians also prescribe use of the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim/Pfizer). Spiriva is expected to constitute about xxx% of the U.S. COPD drug sales in 2012. The LABA/LAMA combination is preferred for the treatment of COPD. Several combinations are in late-stage development, including vilanterol / GSK-573719 (GlaxoSmithKline/Theravance), indacaterol / glycopyrronium (Novartis), and olodaterol / tiotropium (Boehringer Ingelheim).
Key products exposed to generic competition include GlaxoSmithKline’s Advair Boehringer Ingelheim/Pfizer’s Spiriva and Merck’s Singulair, which will lose active ingredient patent protection in the U.S. in 2011 and 2012 respectively. Patent expiration of Merck’s Singulair, which generated sales of around USD 3.3 billion in 2010, will be a key restraint for the overall Asthma market as generic entry in the United States, Europe and Japan will reduce sales of branded Singulair.
Asthma is characterized by recurrent attacks of coughing, chest-tightening, breathlessness and wheezing as the airways narrow and swell that vary in severity and frequency. This chronic disease is most common among children.
Asthma and COPD Drug Market: Overview
The multi-billion dollar global asthma and chronic obstructive pulmonary disease (COPD) drugs market has been expanding at a steady pace, fueled primarily by the growing patient population. The World Health Organization estimates that in 2015, the number of deaths caused by COPD stood at 3 million. The organization also states that at present, there are around 235 million people suffering from asthma around the globe. While both asthma and COPD cannot be cured, the symptoms can be managed and controlled with the help of appropriate medication. These drugs not only help relieve symptoms, but also increase the patient’s exercise capacity and enable them to lead a better life.
This report is designed to guide clients in identifying the main areas of growth in the asthma and COPD drugs market and equip them with the right tools to face the challenges that lie ahead. Major opportunities have been highlighted and suggestions on how to overcome various hurdles have been discussed at length.
Asthma and COPD Drug Market: Trends and Opportunities
The global asthma and COPD drugs market is estimated to value US$26.9 bn by the end of 2017. Poor air quality in several emerging economies of the Middle East and Africa, Asia Pacific, and Latin America – such as India, China, Russia, and Brazil – has resulted in the increased prevalence of various respiratory diseases. This has upped the demand for and consumption of asthma and COPD drugs. Some of the other major factors driving the market are rising geriatric population, growing prevalence of asthma and chronic obstructive pulmonary disease, strong pipeline products, technological advancements, rising health awareness, greater spending on healthcare, and increasing government as well as non-government support and initiatives.
On the down side, certain side effects of asthma and COPD drugs, strict regulatory requirements for drug approvals, and patent expiry of blockbuster drugs threaten to keep this market from realizing its full potential. Be that as it may, developing countries have been providing immense opportunities for growth. The introduction of generic drugs by local and regional players in these countries will open new doors for companies looking to invest in and capitalize on the opportunities presented here.
Asthma and COPD Drug Market: Regional Outlook
North America accounts for a prominent share in the global market for asthma and COPD drugs, with the U.S. emerging as the clear leader. Higher patient awareness and increased prices of asthma and COPD drugs are the primary factors driving the U.S. market in terms of revenue. Strong pipeline studies and products also reflect positively on this market and indicates that the country-wide market will continue to play a major role in the development of the North America market for asthma and COPD drugs. A significant rise in initiatives by government and public bodies and growing investments made by them have also contributed toward the expansion of this market.
However, despite these strong factors in its favor, North America is projected to witness a decline in terms of market share owing to the immense potential of other emerging regional markets. The patent expiry of major blockbuster drugs by pharmaceutical companies based out of North America will also result in a drop in market share.
Asia Pacific continues to be a promising market for asthma and COPD drugs thanks primarily to the rising incidence of respiratory diseases. This can be attributed to alarming air pollution and increased population of smokers.
Companies mentioned in the report
Roche Holding AG (Switzerland), Vectura Group (U.K.), Teva Pharmaceutical Industries (Israel), Novartis AG (Switzerland), Boehringer Ingelheim (Germany), GlaxoSmithKline (GSK) (U.K.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Pfizer (U.S.), and AstraZeneca (U.K.) are some of the prominent companies operating in the global asthma and COPD drug market. Most players in the market have been focusing their capabilities on expanding in emerging economies owing to the immense opportunities available there. Development of innovative products through R&D and clinical trials is also a key growth strategy adopted by players in the asthma and COPD drugs market.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 SCOPE OF THE REPORT
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 ASTHMA AND COPD MARKET
3.1 MARKET OVERVIEW
3.2 INCREASING ASTHMA AND COPD PREVALENCE AND TRENDS
3.2.1 Region wise estimate of asthma patients, 2007-2011(Million)
3.2.1 Region wise Estimate of COPD patients, 2007-2011 (Million)
3.3 PRODUCT TREND ANALYSIS
3.4 ASTHMA DISEASE OVERVIEW
3.4.1 ASTHMA PATIENT FORECASTS BY GEOGRAPHY, 2012 - 2017 (MILLION)
3.4.2 PATIENTS SUFFERING FROM ASTHMA, CHINA, 2012 - 2017 (MILLION)
3.5 COPD DISEASE OVERVIEW
3.6 PATIENT FORECASTS – COPD PATIENTS BY GEOGRAPHY, 2012 – 2017 (MILLION)
3.6.1 PATIENTS SUFFERING FROM COPD, CHINA, 2010 - 2017 (MILLION)
3.7 GROWTH DRIVERS
3.7.1 INCREASE IN POPULATION SUSCEPTIBLE TO INDOOR AIR POLLUTANTS
3.7.2 DAILY EXPOSURE TO HAZARDOUS WORKING ENVIRONMENT LEADS TO GROWTH OF ASTHMA AND COPD
3.7.3 GROWING AGING POPULATION
3.7.4 INCREASING POPULATION OF SMOKERS WILL SUPPORT THE GROWTH OF ASTHMA AND COPD MARKET
3.7.5 INFLUX OF POLLUTANTS IN THE AIR
3.7.6 INCREASE IN DISPOSABLE INCOME AND HEALTHCARE FACILITY
3.8 MARKET RESTRAINTS
3.8.1 PATENT EXPIRY OF MANY BLOCKBUSTER BRANDS WILL CREATE PRESSURE
3.8.2 OVERALL HIGH COST OF ASTHMA TREATMENT IS A CHALLENGE FOR PATIENTS
188.8.131.52 Uninsured people - a challenge
3.8.3 LONG TREATMENT CONTINUATION
3.9 PORTER FIVE FORCES MODEL
3.9.1 BARGAINING POWER OF SUPPLIER
3.9.2 BARGAINING POWER OF BUYER
3.9.3 RIVALRY AMONG EXISTING COMPETITORS
3.9.4 THREAT OF NEW ENTRANTS
3.9.5 THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
CHAPTER 4 ASTHMA AND COPD MARKET BY PRODUCT TYPE
4.1 ASTHMA AND COPD DRUG REVENUE FORECASTS
4.2.1 REVENUE FORECASTS FOR BRONCHODILATORS
4.2.2 SHORT ACTING BRONCHODILATORS
184.108.40.206 Revenue Forecasts for Short-Acting Bronchodilators
4.2.3 LONG-ACTING BRONCHODILATORS
220.127.116.11 Revenue Forecasts for Long-Acting Bronchodilators
4.2.4 ANTICHOLINERGICS BRONCHODILATORS
18.104.22.168 Revenue Forecasts Anticholinergics
22.214.171.124 Revenue Forecasts for Anti-Inflammatories
4.3.2 INHALED CORTICOSTEROIDS
126.96.36.199 Revenue Forecasts for Inhaled Corticosteroids
188.8.131.52 Revenue Forecasts for Anti-Leukotrienes
4.3.4 MONOCLONAL ANTIBODIES
184.108.40.206 Revenue Forecasts for Monoclonal Antibodies
4.4 COMBINATION THERAPIES
4.4.1 REVENUE FORECASTS FOR COMBINATION THERAPIES
CHAPTER 5 ASTHMA DRUG MARKET ANALYSIS
5.1 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
5.2 ASTHMA PATHOPHYSIOLOGY
5.3 ASTHMA DRUG REVENUE BY BRNAD, 2009 - 2011 (USD MILLION)
220.127.116.11 Short-Acting Beta2-Agonists
18.104.22.168 Inhaled Corticosteroids
22.214.171.124 Long-Acting Bronchodilators
126.96.36.199 Leukotriene Modifiers
188.8.131.52 Mast Cell Stabilizers
184.108.40.206 Monoclonal Antibodies
220.127.116.11 Oral Corticosteroids
5.4.1 MEDICATION ADHERENCE BY AGE GROUP, 2011
5.5 ASTHMA - COST TRENDS
5.6 EMERGING TREATMENT OPTIONS FOR ASTHMA
CHAPTER 6 COPD MARKET ANALYSIS
6.1 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
6.2 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION)
6.3 EXISTING MEDICATION FOR COPD
6.4 COPD DRUG MARKET SHARE 2011 VS 2017
6.4.2 LONG-ACTING ANTICHOLINERGICS
6.4.3 LONG-ACTING Β2-AGONISTS
6.4.4 SHORT-ACTING BRONCHODILATORS
6.5 INHALED CORTICOSTEROIDS
6.6 COMBINATION THERAPIES
6.6.1 Β2-AGONISTS AND ANTICHOLINERGICS
6.6.2 LABAS AND INHALED CORTICOSTEROIDS
6.7 EMERGING TRENDS IN COPD THERAPY
CHAPTER 7 DRUG BRAND DYNAMICS
7.1 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014
7.2 SYMBICORT REVENUE (USD MILLION), 2009 – 2014
7.3 SPIRIVA REVENUE (USD MILLION), 2009 - 2014
7.4 SINGULAIR REVENUE (USD MILLION), 2009 - 2014
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 COMPETITIVE STRATEGY BY KEY PLAYERS
8.2 MARKET SHARE BY KEY PLAYERS, 2011
8.3 KEY ASTHMA & COPD DRUGS BY REVENUE, 2009 – 2011 (USD MILLION)
CHAPTER 9 COMPANY PROFILE
9.1 NOVARTIS AG
9.1.1 COMPANY OVERVIEW
9.1.2 FINANCIAL OVERVIEW:
9.1.3 RESPIRATORY DIVISION NET SALES
9.1.4 SEGMENT OVERVIEW
9.1.5 GEOGRAPHICAL OVERVIEW
9.1.6 RECENT DEVELOPMENT
9.2 MERCK & CO.
9.2.1 COMPANY OVERVIEW
9.2.2 FINANCIAL OVERVIEW:
9.2.3 GEOGRAPHICAL OVERVIEW
9.2.4 RECENT DEVELOPMENT
9.3 GLAXOSMITHKLINE PLC
9.3.1 COMPANY OVERVIEW
9.3.2 FINANCIAL OVERVIEW:
9.3.3 SEGMENT OVERVIEW
9.3.4 GEOGRAPHICAL OVERVIEW
9.3.5 RECENT DEVELOPMENT
9.4 BOEHRINGER INGELHEIM GMBH (BOEHRINGER)
9.4.1 COMPANY OVERVIEW
9.4.2 FINANCIAL OVERVIEW:
9.4.3 SEGMENT OVERVIEW
9.4.4 GEOGRAPHICAL OVERVIEW
9.4.5 RECENT DEVELOPMENT
9.5.1 COMPANY OVERVIEW
9.5.2 FINANCIAL OVERVIEW:
9.5.3 GEOGRAPHICAL OVERVIEW
9.5.4 RECENT DEVELOPMENT
LIST OF FIGURES
FIG. 1 REGION WISE ESTIMATE OF ASTHMA PATIENTS, 2007-2011 (MILLION)
FIG. 2 REGION WISE ESTIMATE OF COPD PATIENTS, 2007-2011 (MILLION)
FIG. 3 CHINESE ASTHMA PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)
FIG. 4 CHINESE COPD PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)
FIG. 5 AIR POLLUTION MARKET SHARE FROM DIFFERENT INDUSTRIES
FIG. 6 CHILDREN AGED (0-18) UNINSURED PERCENTAGE, 2003 - 2010
FIG. 7 ASTHMA AND COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 8 BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 9 SHORT-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 10 LONG-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 11 ANTICHOLINERGICS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 12 ANTI-INFLAMMATORIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 13 INHALED CORTICOSTEROIDS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 14 ANTI-LEUKOTRIENES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 15 MONOCLONAL ANTIBODIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 16 COMBINATION THERAPIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 17 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 18 ASTHMA DRUG REVENUE BY BRNAD, 2009- 2011 (USD MILLION)
FIG. 19 MEDICATION ADHERENCE BY AGE GROUP, 2011
FIG. 20 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 21 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION)
FIG. 22 COPD DRUG MARKET SHARE 2011 VS 2017
FIG. 23 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014
FIG. 24 SYMBICORT REVENUE (USD MILLION), 2009 - 2014
FIG. 25 SPIRIVA REVENUE (USD MILLION), 2009 - 2014
FIG. 26 SINGULAIR REVENUE (USD MILLION), 2009 - 2014
FIG. 27 PULMICORT REVENUE (USD MILLION), 2009 - 2014
FIG. 28 MARKET SHARE BY KEY PLAYERS, 2011
FIG. 29 NOVARTIS AG, PERFORMANCE CHART (2007-2011)
FIG. 30 NOVARTIS AG, MARKET SHARE BY SEGMENT IN 2011
FIG. 31 NOVARTIS AG, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011)
FIG. 33 MERCK & CO. MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 34 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010)
FIG. 35 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2010
FIG. 36 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 37 BOEHRINGER INGELHEIM, MARKET SHARE BY SEGMENT IN 2011
FIG. 38 BOEHRINGER INGELHEIM, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 39 NYCOMED, MARKET SHARE BY GEOGRAPHY IN 2010